Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
Status:
Terminated
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
M3814 is an investigational drug under evaluation for treatment of lung cancer. The purpose
of the study was to assess the Safety and Efficacy of M3814 in combination with chemotherapy
with SCLC ED.